India Operations
Overview
In 2009-10 we crossed the Rs. 10,000 million milestone with total sales of Rs. 10,211 million. 67% of this was contributed by our India operations.
Presence
- Diabetes
- Cardiovascular
- Orthopaedics
- Nutritional
- Dermatology/Cosmetology
- Gynaecology
- Paediatrics
- CNS
- Respiratory
Presence in Nutritional, Gynaecology and Respiratory segments through innovative products from partners in USA and Europe and in Cosmetology with a leading European brand.
Market standing
- Ranked 24th in the Indian pharmaceutical industry (Source: IMS March 2010).
- Leader by Rx in Diabetes & Cardiology segments.
We are the leaders in the oral anti-diabetic segment n India in terms of both prescriptions and value. It is a position we have held consistently for almost two decades. Our anti-diabetes portfolio, which includes insulin, contributes to 39% of our sales.
We are also leaders in the cardiovascular disease segment in terms of prescription generation. In terms of value, we rank amongst the first 10 companies in India. The cardiology portfolio contributes to 31% to our sales.
We have a significant presence in dermatology and are leaders in the anti-acne segment. We have launched the Sebamed range of skin-care products from Europe.